Tag: Vyome
Analyst values Vyome’s VT-1953 at USD 1 Billion upon successful completion...
Third-party analysis estimates the total addressable U.S. market to be approximately USD 2.2 billion
“Our focus is on identifying biological mechanisms that may offer alternative...
Venkat Nelabhotla, Co-Founder, President, and CEO of Vyome Holdings, Inc. shared his insights on the company's long-term vision, its current focus areas, R&D efforts and future outlook
Vyome reports positive final phase 2 results for VT-1953; Plans to...
Based on these positive Phase 2 results, the company plans to advance VT-1953 into a pivotal study following discussions with the FDA to seek approval to enter $1B potential addressable market opportunity
Vyome Therapeutics begins phase 2 trial of its drug for acne...
The company has dosed the first patient in its Phase 2 trial of the Company’s lead clinical candidate, VB-1953, for the treatment of moderate to severe inflammatory acne vulgaris......................